SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-036142
Filing Date
2020-08-04
Accepted
2020-08-04 16:33:49
Documents
83
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q srne-10q_20200630.htm   iXBRL 10-Q 2770574
2 EX-10.3 srne-ex103_111.htm EX-10.3 3603
3 EX-31.1 srne-ex311_7.htm EX-31.1 17154
4 EX-31.2 srne-ex312_10.htm EX-31.2 17054
5 EX-32.1 srne-ex321_9.htm EX-32.1 14924
  Complete submission text file 0001564590-20-036142.txt   10396717

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA srne-20200630.xsd EX-101.SCH 69712
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE srne-20200630_cal.xml EX-101.CAL 74527
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE srne-20200630_def.xml EX-101.DEF 270376
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE srne-20200630_lab.xml EX-101.LAB 508500
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE srne-20200630_pre.xml EX-101.PRE 421846
11 EXTRACTED XBRL INSTANCE DOCUMENT srne-10q_20200630_htm.xml XML 2139611
Mailing Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121
Business Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121 858-203-4100
Sorrento Therapeutics, Inc. (Filer) CIK: 0000850261 (see all company filings)

IRS No.: 330344842 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36150 | Film No.: 201073785
SIC: 2836 Biological Products, (No Diagnostic Substances)